Cushing's Syndrome
Osilodrostat improves physical manifestations of hypercortisolism for most adults
SAN DIEGO — Osilodrostat is associated with improvements in physical manifestations of hypercortisolism and reductions in mean body weight and BMI in adults with Cushing’s syndrome, according to a speaker.
LOGICS: Levoketoconazole improves cortisol control in endogenous Cushing’s syndrome
SAN DIEGO — Compared with placebo, levoketoconazole improved cortisol control and serum cholesterol levels for adults with endogenous Cushing’s syndrome, according to results from the LOGICS study presented here.
Immunohistochemistry-guided sequencing finds mutations in most cortisol-producing adenomas
The use of an immunohistochemistry‒guided targeted amplicon sequencing approach using formalin-fixed, paraffin-embedded tissue detected somatic mutations in more than 70% of cortisol-producing adenomas, according to study data.
FDA approves levoketoconazole for Cushing’s syndrome
The FDA approved the steroidogenesis inhibitor levoketoconazole for adults with Cushing’s syndrome for whom surgery is not an option or has not been curative, according to an industry press release.
Free cortisol evaluation ‘useful’ after abnormal dexamethasone test
An assessment of free cortisol after a dexamethasone suppression test could add value to the diagnostic workup of hypercortisolism, which can be plagued by false-positive results, according to data from a cross-sectional study.
FDA accepts NDA for novel Cushing’s syndrome treatment
The FDA accepted for review a new drug application for the steroidogenesis inhibitor levoketoconazole for the treatment of endogenous Cushing’s syndrome, according to an industry press release.
Mortality rate in Cushing’s syndrome ‘unacceptably high’
A large study of mortality in Cushing’s syndrome calculated a threefold higher mortality rate for these patients, with cerebrovascular and atherosclerotic vascular diseases and infection accounting for 50% of deaths, researchers reported.
Thyroid dysfunction highly prevalent in Cushing’s syndrome
Central hypothyroidism is prevalent in about 1 in 2 adults with Cushing’s syndrome, and thyroid function can be restored after curative surgery for most patients, according to study findings.
New data further support novel treatment for Cushing’s syndrome
The steroidogenesis inhibitor levoketoconazole improved and normalized morning urinary free cortisol concentrations for adults with endogenous Cushing’s disease compared with placebo, according to an industry press release.
Topline data show safety, efficacy of Cushing’s disease therapy
Adults with Cushing’s disease who took the cortisol synthesis inhibitor osilodrostat were more likely to sustain a normal mean urinary free cortisol level vs. placebo, according to press release from Recordati Rare Diseases.